<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000999'>Pyoderma</z:hpo> gangrenosum is a dermatologic manifestation of <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e> such as <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e>, <z:e sem="disease" ids="C1136085" disease_type="Neoplastic Process" abbrv="">monoclonal gammopathy</z:e>, <z:hpo ids='HP_0001369'>arthritis</z:hpo>, <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000999'>Pyoderma</z:hpo> gangrenosum can be stabilized with oral <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> administration </plain></SENT>
<SENT sid="2" pm="."><plain>After stabilization, it can be managed with debridement and skin graft </plain></SENT>
</text></document>